Hernia, Ventral
0
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
TELA BioPA - Malvern
2 programsOviTex 1S PermanentN/A1 trial
OviTex Reinforced Tissue MatrixN/A1 trial
Active Trials
Sharp TherapeuticsPA - Pittsburgh
1 programPatients will be randomized to moderateN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
TELA BioOviTex Reinforced Tissue Matrix
Sharp TherapeuticsPatients will be randomized to moderate
TELA BioOviTex 1S Permanent
Clinical Trials (3)
Total enrollment: 252 patients across 3 trials
Ventral or Inguinal Hernia, Robotically Repaired With OviTex Mesh
Start: Apr 2021Est. completion: Dec 2029160 patients
N/ARecruiting
Prospective Randomized Trial of Moderate vs Deep Neuromuscular Blockade During Laparoscopic Ventral Hernia Repair
Start: Aug 2017Est. completion: Feb 20220
N/AWithdrawn
Ventral Hernia Study Using OviTex Reinforced Bioscaffold
Start: Apr 2017Est. completion: Aug 202192 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 252 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.